Skip to main content Skip to section navigation Skip to footer
Achieve Life Sciences, Inc. IR Overview
Achieve Life Sciences Logo
  • Home
  • About
  • Products
  • Investors
  • News
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Information
    • Overview
    • Management Team
    • Contacts
  • Financial Information
    • Overview
    • Financial Results
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Information
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Nov 15, 2022 8:00 am EST
Achieve Life Sciences Announces Private Placement of $18.9 Million
Nov 14, 2022 4:05 pm EST
Achieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update
Nov 8, 2022 8:00 am EST
Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial
Oct 31, 2022 8:00 am EDT
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022
Sep 27, 2022 8:00 am EDT
Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Sep 7, 2022 8:00 am EDT
Achieve Life Sciences Announces Participation at Fall Investor Conferences
Aug 11, 2022 4:05 pm EDT
Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update
Jul 28, 2022 8:00 am EDT
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022
Jul 1, 2022 4:05 pm EDT
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
Jun 29, 2022 8:00 am EDT
Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
  • US Headquarters
  • 22722 29th Dr SE,
    Suite 100
  • Bothell, WA 98021
  • Phone: (425) 686-1500
  • Vancouver Office
  • 1040 W Georgia Street,
    Suite 1030
  • Vancouver, BC V6E 4H1

About

  • About
  • Management Team
  • Board of Directors
  • Scientific Advisors
  • Careers

For Investors

  • Investors
  • News
  • Corporate Governance
  • Financial Information
  • SEC Filings

Recent News

April 21, 2025
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
More News

© Copyright 2025 | Achieve Life Sciences, Inc. All Rights Reserved

  • Privacy Policy
  • Disclaimer
  • Contact
  • twitter
  • linkedin